Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsPsychotherapy — behavioural therapies

Psych MEQs / SAQs · Psychotherapy — behavioural therapies

Exposure and response prevention for residual OCD on an SRI (MEQ)

FRANZCP/MRCPsych-style MEQ on ERP definition, technique, landmark evidence, fidelity, and SRI combination for residual OCD.

20 marks25 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 29-year-old software engineer with DSM-5-TR OCD (contamination and checking) has been on sertraline 200 mg oral daily for five months with partial benefit (Y-BOCS fell from 28 to 20). He washes for two hours daily, seeks partner reassurance, and avoids public toilets. He has had 'CBT' for eight sessions that were mostly supportive discussion without homework exposures. He declines antipsychotics. (i) Define ERP and explain the maintaining cycle it targets. (ii) Outline assessment steps and hierarchy design for this man, including family accommodation. (iii) Summarise landmark trial evidence relevant to offering EX/RP now (include Foa 2005 and Simpson augmentation trials). (iv) List four fidelity failures that would make further 'CBT' look like non-response. (v) State how you would integrate ongoing sertraline with ERP and when you would step up care. (20 marks)

Model answer

Reveal model answer

(i) Definition and cycle. ERP/EX/RP is structured behavioural treatment in which the patient confronts obsession-evoking cues while systematically refraining from compulsions and other safety behaviours.[13] Obsessions/triggers raise distress; rituals (washing, checking, reassurance) reduce distress short-term; that negative reinforcement maintains OCD. ERP breaks the relief loop so expectancy violation and inhibitory safety learning can occur.[12][13]

(ii) Assessment and hierarchy. Confirm OCD dimensions, time occupied, covert rituals, depression/suicide risk, insight, and goals. Measure severity with Y-BOCS.[14] Inventory partner reassurance and any family cleaning/checking (accommodation). Build a collaborative hierarchy from moderate public-contact and bathroom-related tasks up to higher items (e.g. toilet seat contact) with explicit response-prevention rules (delayed/no washing; no reassurance questions; limited checking). Include imaginal items if harm fears co-travel with checking. Plan therapist-assisted then self-directed practices and partner coaching to stop accommodation.[13]

(iii) Evidence for offering EX/RP now. Foa 2005: EX/RP superior to clomipramine alone; combination not clearly better than EX/RP alone at 12 weeks in that design — supports behavioural treatment as a potent standalone and combined modality.[1] For SRI residual symptoms, Simpson 2008 showed EX/RP superior to stress management augmentation; Simpson 2013 showed EX/RP superior to risperidone and placebo augmentation — aligning with his preference to add EX/RP rather than antipsychotic first when acceptable and available.[2][3] Prior "supportive CBT" was not adequate-dose ERP, so he has not yet had an evidence-based behavioural trial.

(iv) Fidelity failures. Examples: no between-session exposures; allowing washing/reassurance after contact; therapist providing repeated safety reassurance; hierarchy never leaving mild items; sessions without agenda/homework review; family undoing practice at home.[13][15]

(v) Integration and step-up. Continue sertraline 200 mg oral daily if tolerated (monitor activation, sexual side effects, hyponatraemia risk, interactions) while delivering twice-weekly or high-homework weekly EX/RP; do not stop SRI solely to "start therapy."[2][3] Step up if non-response after adequate ERP dose/fidelity: intensify schedule/residential ERP, review SRI optimisation or clomipramine pathway, treat depression/risk, specialist OCRD service — not premature polypharmacy without behavioural trial.[13]

Common errors

Calling supportive talk ERP; recommending risperidone before EX/RP without rationale; omitting response prevention; ignoring family accommodation; claiming combination always beats EX/RP alone after Foa 2005; stopping sertraline reflexively; no Y-BOCS monitoring plan.[1][3][13][14]

References

  1. [1]Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry, 2005.PMID 15625214
  2. [2]Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder Am J Psychiatry, 2008.PMID 18316422
  3. [3]Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial JAMA Psychiatry, 2013.PMID 24026523
  4. [12]Craske MG, Treanor M, Conway CC, et al. Maximizing exposure therapy: an inhibitory learning approach Behav Res Ther, 2014.PMID 24864005
  5. [13]Hezel DM, Simpson HB Exposure and response prevention for obsessive-compulsive disorder: A review and new directions Indian J Psychiatry, 2019.PMID 30745681
  6. [14]Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability Arch Gen Psychiatry, 1989.PMID 2684084
  7. [15]Wheaton MG, Galfalvy H, Steinman SA, et al. Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes adherent? Behav Res Ther, 2016.PMID 27497840